Because a patent and exclusivity rights are in place until September 2024, companies are not allowed to make a generic version of Cometriq (cabozantinib) at this time. However, after the patent and exclusivity rights expire, a generic product may become available. Certain circumstances may come up, such as lawsuits or patents for new uses, that may further delay the availability of a generic version.
Can I Buy Generic Cometriq?
Cometriq™ (cabozantinib) is a prescription medication used in the treatment of advanced medullary thyroid cancer. It is used when the cancer has spread to other areas of the body (metastasized).
Cometriq is made by Catalent Pharma Solutions, Inc., for Exelixis, Inc. It is currently under the protection of a patent and exclusivity rights that prevent any generic versions from being manufactured in the United States.
When Will a Generic Version Be Available?
The first patent for Cometriq is set to expire in September 2024. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period, including things such as lawsuits or other patents for new Cometriq uses. Once the patent expires, there may be several companies that manufacture a generic Cometriq drug.
Is Cabozantinib a Generic Cometriq?
No -- cabozantinib is the active ingredient in Cometriq, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name." The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Cometriq [package insert]. South San Francisco, CA: Exelixis;2012 November.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed April 25, 2013.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click